India’s Top 500 Value Creators 2023

India’s Top 500 Value Creators 2023 | 59 [ EXPERT’S VIEW ] What are some of the key milestones in Marksans Pharma’s journey as a value creator? The journey of our company has been both challenging and rewarding. Our vision is to create a global pharmaceutical company and we are having continuous and sustainable growth towards our vision. As a value-driven company, we prioritize corporate responsibility and adhering to the highest standards of ethical conduct and transparency. We have had various milestones in our journey through our focus on our front-end business model and concentration of the OTC business segment. 1. We are now a partner of choice with most of our customers: We increase access to products, and low-cost manufactur ing, and bring mass customization and quality expertise.we are directly distributing our products to most of large pharmacies & groceries in USA, UK & Australia Mark Saldana Chairman and Managing Director Marksans Pharma Ltd 2. We expanded our manufacturing capacity from 18 bn units to 26 bn units through the acquisition of Teva Pharma’s manufacturing unit in Goa, India. This move assists us with scalability and responsiveness t o ma r k e t dema nd . Ou r 4 manufacturing facilities are spread across USA, India & UK. They have accreditions fromUSFDA, UKMHRA , EU & Australian Health Authorities. 3. Expansion has played an important role in our growth strategy, with successful front-end companies in the UK, US, and Australia, we have expanded our front-end reach to the Middle East through the acquisition of Access Healthcare in UAE. 4. Financial mi lestones, such as investment froma strategic partner, Orbimed. Nearing INR 2000 crore revenue in FY24 as promised. One of the leading Indianpharmaceutical firms in the UK in terms of revenue. There has been margin expansion due to our operational efficiency strategies. Completed buyback of INR 32 Crore in FY23. USA revenue are reaching around USD 100 million. With the new increased capacity we have aggressive road map of doubling our revenues in next couple of years. We will continue to have various milestones in the coming journey o f g r owt h a l ong wi t h deep - seated responsibility towards our shareholders. What key initiatives has the company taken to enhance operational efficiency and overall productivity in its business operations? In our continuous commitment to improvement, we have undertaken several strategic initiatives to bolster our operat iona l ef f i c iency and productivity, 1. Our focus area has been the integrationof advancedautomation and robotics into our production lines. We have also implemented lean principles enabling us for continuous process improvement and to identify areas of waste and inefficiency. 2. Digital transformation has been a key driver for helping us drive operational efficiencies, real-time data analytics has been put in place, which allows us to monitor our process and quickly respond to deviation from expected output, using col laborat ion tools and platforms are teams and partners can effectively communicate and work. How is the company leveraging data and technology to improve its business resilience? 1. D a t a a n d t e c h n o l o g y a r e important to our strategy, we have invested in data analytics to get real-time insights into our day- to-day operations. We are using data-driven decision-making to identify any variation in desired performance. Du n & Bradstreet

RkJQdWJsaXNoZXIy MTI0MjY3OQ==